CUPERTINO, Calif., March 29, 2005 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation
(Nasdaq: DRRX) announced today that it will present at the CIBC World Markets
Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is
taking place April 4-5th at The Millennium Broadway Hotel in New York City,
New York. James E. Brown, DVM, President and Chief Executive Officer will be
presenting at the conference on Monday, April 4th at 2:15 p.m. Eastern Time.
There will be a live webcast of the presentation from the Conference. The
webcast will be available on DURECT’s website under the Event Calendar section
of “Investor Relations.” The presentation will also be available for replay on
DURECT’s website for a period of up to 30 days after the conference.
DURECT Corporation is an emerging specialty pharmaceutical company focused
on the development of pharmaceutical systems based on its proprietary drug
delivery platform technologies that treat chronic debilitating diseases and
enable biotechnology products. These platform technologies include the
SABER(TM) Delivery System (a patented and versatile depot injectable useful
for protein and small molecule delivery), the ORADUR(TM) sustained release
oral gel-cap technology (an oral sustained release technology with several
potential abuse deterrent properties), the DURIN(TM) Biodegradable Implant
(drug-loaded implant system), the TRANSDUR(TM) transdermal technology and the
MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system).
DURECT also collaborates with pharmaceutical companies to develop and
commercialize proprietary and enhanced pharmaceutical products based on its
technologies. DURECT has five disclosed on-going development programs of which
four are in collaboration with pharmaceutical partners. Additional information
about DURECT is available at www.www.durect.com.
NOTE: SABER(TM), ORADUR(TM), DURIN(TM), TRANSDUR(TM) and MICRODUR(TM) are
trademarks of DURECT Corporation. Other referenced trademarks belong to their
SOURCE DURECT Corporation
Schond L. Greenway
Executive Director, IR and Strategic Planning of DURECT